drugset / Trial / NCT02093819
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers
RandomizedParallel-groupSingle-blindTreatment
Summary
To investigate the safety and tolerability of BI 416970 and to assess the pharmacokinetics (PK) of single rising doses of BI 416970. A further objective is to assess the influence of CYP2C9 phenotype on the PK of BI 416970.
Timeline
- Start
- 2014-04
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 416970 | Unknown | — | — |
Indications
No indication recorded.